{"id":"enstilar-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Betamethasone dipropionate acts as a glucocorticoid receptor agonist, suppressing inflammatory cytokines and immune cell infiltration in the skin. Calcipotriene is a vitamin D3 analog that promotes keratinocyte differentiation and reduces proliferation. Together, they provide complementary anti-inflammatory and anti-proliferative effects with potentially improved efficacy and safety compared to corticosteroid monotherapy.","oneSentence":"Enstilar foam combines a potent corticosteroid (betamethasone dipropionate) with a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:17.978Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis in adults"}]},"trialDetails":[{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":"Psoriasis Vulgaris, Psoriasis, Skin Diseases","enrollment":12},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":"Psoriasis Vulgaris","enrollment":182},{"nctId":"NCT04580537","phase":"PHASE2","title":"Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2020-10-02","conditions":"Nail Psoriasis","enrollment":11},{"nctId":"NCT04380597","phase":"","title":"Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life","status":"COMPLETED","sponsor":"Angeles Florez","startDate":"2019-03-26","conditions":"Nail Psoriasis","enrollment":10},{"nctId":"NCT02935582","phase":"","title":"PSOREAL - Managing PSOriasis in the REAL World","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-01","conditions":"Psoriasis Vulgaris","enrollment":1214},{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Plaque Psoriasis, Psoriasis","enrollment":25},{"nctId":"NCT03731091","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2018-10-31","conditions":"Psoriasis Vulgaris","enrollment":494},{"nctId":"NCT02881346","phase":"","title":"Efficacy and Tolerability of Enstilar® in Daily Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-09","conditions":"Plaque Psoriasis","enrollment":410},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03080545","phase":"PHASE4","title":"Enstilar in Combination With Biologic Agents","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2017-05-01","conditions":"Psoriasis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enstilar 0.005%-0.064% Topical Foam","calcipotriene and betamethasone dipropionate"],"phase":"marketed","status":"active","brandName":"Enstilar® foam","genericName":"Enstilar® foam","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enstilar foam combines a potent corticosteroid (betamethasone dipropionate) with a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}